Adimab
Overview
Adimab's yeast-based discovery platform functions as a synthetic human immune system to create novel antibody therapeutics across an extensive range of diseases, including cancer as well as autoimmune and infectious diseases. We are a profitable privately-held biotech company, backed by top-tier venture capital firms including Google Ventures, OrbiMed Advisors, Polaris Partners, and SV Life Sciences. We are unique in our ability to take a long-term view on value creation which allows us to continuously refine and improve our technology and make substantial investments in R&D.
Reach Adimab directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Adimab
Who are the partners at Adimab?
Team members listed for Adimab include Jessica Dawson (Assoc. Director).
How do I contact Adimab?
Adimab's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database